CDK12-IN-E9

• Description:

  CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC50> 1 μM[1].

• Product Name Alternative:

  (1α,1'S,4β)-AZD3293; (1α,1'S,4β)-LY3314814

• UNSPSC:

  12352005

• Target:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk12-in-e9.html

• Purity:

  99.71

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  C=CC(NC1=CC=CC(NC2=CC(N3[C@H](CCO)CCCC3)=NC4=C(CC)C=NN24)=C1)=O

• Molecular Formula:

  C24H30N6O2

• Molecular Weight:

  434.53

• References & Citations:

  [1]Gao Y, et al. Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. Cell Chem Biol. 2018 Feb 15;25 (2) :135-142.e5.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK12; CDK2; CDK7; CDK9

• CAS Number:

  [2020052-55-3]